Table 2.
Cost model inputs.
| Input | Value | Source |
|---|---|---|
| Screening | ||
| Test offer and voluntary counselling cost (regardless of uptake); 20-min consultation | CHF 62.53 | TarMed Suisse. Tariff version: 1.09, from Jan 1, 2018. TARMED CT00.0010 + CT00.0020 + CT00.0030 |
| Pretest discussion cost; 5-min consultation | CHF 17.86 | TarMed Suisse. Tariff version: 1.09, from Jan 1, 2018. TARMED CT00.0050 |
| Cost of communicating results, HCV viraemia negative; 5-min consultation | CHF 17.86 | TarMed Suisse. Tariff version: 1.09, from Jan 1, 2018. TARMED CT00.0050 |
| Cost of communicating results, HCV viraemia positive; 20-min consultation | CHF 62.53 | TarMed Suisse. Tariff version: 1.09, from Jan 1, 2018. TARMED CT00.0010 + CT00.0020 + CT00.0030 |
| Cost of antibody test | CHF 66.00 | TarMed Suisse. Tariff version: 1.09, from Jan 1, 2018. TARMED CA3070.00 (HCV, Ig or IgG, test) |
| Cost of RNA test (quantitative PCR for HCV) | CHF 180.00 | TarMed Suisse. Tariff version: 1.09, from Jan 1, 2018. TARMED CA3073.00 (HCV, RNA amplification) |
| Cost of FibroScan (including consultation) | CHF 183.55 | TarMed Suisse. Tariff version: 1.09, from Jan 1, 2018. TARMED CT00.0056 + CT00.0161 + CT39.3515 + CT39.3660 + CT00.2285 |
| Confirmation of diagnosis if HCV positive | CHF 180.00 | TarMed Suisse. Tariff version: 1.09, from Jan 1, 2018. TARMED CA3073.00 |
| Treatment, including drug acquisition, monitoring and resource use | ||
| Lifetime cost per infected person (no antiviral treatment) | CHF 15,970 | Scott et al. 20163 |
| Lifetime cost per infected person (early treatment) | CHF 55,336 | Scott et al. 20163 |
CHF, Swiss francs; HCV, hepatitis C virus; HUG, University Hospitals of Geneva; PCR, polymerase chain reaction; RNA, ribonucleic acid.